Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the obesity medicine field pushes ahead.